论文部分内容阅读
目的观察尤瑞克林联合丁苯酞治疗急性脑梗死的临床疗效。方法将急性脑梗死患者80例采用抽签法分为治疗组和对照组各40例,对照组给予抗血小板和脑保护等神经内科常规治疗,治疗组在对照组治疗的基础上给予尤瑞克联合丁苯酞治疗,比较2组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分和临床疗效。结果治疗前2组NIHSS评分比较差异无统计学意义(P>0.05);治疗后2组NIHSS评分均有下降,且治疗组明显低于对照组,差异有统计学意义(P<0.05或P<0.01)。治疗组总有效率为87.50%明显高于对照组的70.00%,差异有统计学意义(P<0.01)。结论尤瑞克林联合丁苯酞治疗急性期脑梗死疗效显著,值得临床推广。
Objective To observe the clinical efficacy of uracil combined with butylphthalide in the treatment of acute cerebral infarction. Methods Eighty patients with acute cerebral infarction were divided into treatment group and control group with 40 cases in each group. The control group was given conventional therapy of neurology such as platelet and brain protection. The treatment group was given the combination of Yurikel Butylphthalide treatment, the two groups before and after treatment, the National Institutes of Health Stroke Scale (NIHSS) score and clinical efficacy. Results There was no significant difference in NIHSS score between the two groups before treatment (P> 0.05). NIHSS scores of two groups decreased after treatment, and the treatment group was significantly lower than the control group (P <0.05 or P < 0.01). The total effective rate of the treatment group was 87.50%, which was significantly higher than that of the control group (70.00%), the difference was statistically significant (P <0.01). Conclusion The combination of uracil and butylphthalide in the treatment of acute cerebral infarction has significant curative effect and is worthy of clinical promotion.